Publication | Open Access

Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma

Hematological MalignancyOncologyMedicineImmunologyDendritic Cell TherapyMultiple MyelomaPotent Anti-myeloma EfficacyImmune Checkpoint InhibitorImmunotherapyPharmacologyTumor Microenvironment